Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Exec. VP, Strat. & Mkt Dev. | December 10, 2018 | December 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date December 10, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 · Expires 2027-05-04 | Direct | 85,710 |
Reported balance
After 2018-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-10 · Grant · Acquired 85,710 · Balance 85,710 F2: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 42,222 shares of common stock of Organogenesis for $7.01 per share. F1: 100% of the shares subject to this option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 · Expires 2027-05-04 | Direct | 203,000 |
Reported balance
After 2018-12-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-10 · Grant · Acquired 203,000 · Balance 203,000 F4: Received in connection with the Merger in exchange for an option to acquire 100,000 shares of common stock of Organogenesis for $7.01 per share. F3: The shares underlying the option shall vest 20% annually beginning on December 31, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to this option are fully vested and exercisable.
F2: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 42,222 shares of common stock of Organogenesis for $7.01 per share.
F3: The shares underlying the option shall vest 20% annually beginning on December 31, 2018.
F4: Received in connection with the Merger in exchange for an option to acquire 100,000 shares of common stock of Organogenesis for $7.01 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 13, 2018 01:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 203,000 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000045 · edgar.xml · derivative · entry 2 Walthall Howard · CIK 0001759244 · Exec. VP, Strat. & Mkt Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,000 Underlying: Common Stock · 203,000 shares Expires 2027-05-04 F4 · price: Received in connection with the Merger in exchange for an option to acquire 100,000 shares of common stock of Organogenesis for $7.01 per share. F3 · derivative.exercise_date: The shares underlying the option shall vest 20% annually beginning on December 31, 2018. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 85,710 | Not disclosed Strike: $3.46 | Not disclosed |
DisclosureSEC source: 0001661181-18-000045 · edgar.xml · derivative · entry 1 Walthall Howard · CIK 0001759244 · Exec. VP, Strat. & Mkt Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,710 Underlying: Common Stock · 85,710 shares Expires 2027-05-04 F2 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 42,222 shares of common stock of Organogenesis for $7.01 per share. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.